Abstract 2536
Background
TG4001 is a vaccine targeting HPV E6 and E7. It has shown to provide histological clearance of cervical pre-cancerous lesions (Harper DM et al. 2019). We aimed to evaluate in the Ph Ib part the safety of TG4001 in combination with avelumab in HPV 16-positive cancers (NCT03260023).
Methods
Patients with HPV-16 positive cancers who had received ≤ 2 prior regimens for R/M disease were enrolled to either one of the two doses of the vaccine (5x106 and 5x107 pfu). TG4001 was administered SC weekly for 6 weeks, every 2 weeks up to M6, and every 12 weeks thereafter. Avelumab was given IV at 10mg/kg every 2 weeks. Tumor response was assessed by RECIST 1.1. For translational and immunological assessments, PBMC samples were collected longitudinally and tissue samples were collected at baseline and D43.
Results
Nine patients with oropharyngeal (5), anal (2), cervical (1) or vaginal (1) cancer, were enrolled in this trial, 3 patients on the low dose and 6 patients on the high dose of TG4001. No dose-limiting toxicity and no SAE have been observed. 3 patients had a confirmed partial response according to RECIST1.1. 3/5 evaluable patients for T-cell response by ELISPOT displayed detectable peripheric responses against E6 and/or E7 after treatment, and an overall trend to decreased circulating regulatory T cells (Treg). At the tissue level, 4/5 evaluable patients showed an increase of CD8 infiltration and/or a decrease in infiltrated Treg/CD8 ratio at day 43. The percentage of PD-L1+ cells doubled in all low or moderate expressors. The phenotypic findings were supported by increased expression of genes associated with both adaptive and innate immunity and with a shift from a “cold” tumor to a “hot” tumor gene signature.
Conclusions
The combination of TG4001 and avelumab is safe and provides anti-tumor activity in HPV-16+ cancer patients. The treatment induces immune changes in patients with poor baseline immune contexture. The combination is being evaluated in the ongoing Ph II part.
Clinical trial identification
NCT03260023.
Editorial acknowledgement
Legal entity responsible for the study
Transgene SA.
Funding
Transgene.
Disclosure
C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Roche; Advisory / Consultancy: Amgen; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Nanobiotix; Advisory / Consultancy: GSK. J. Delord: Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Research grant / Funding (institution): MSD; Advisory / Consultancy: EMD Serono; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): AstraZeneca. P. Cassier: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche/Genentech; Honoraria (self), Research grant / Funding (institution): Blueprint Medicines; Honoraria (self), Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Plexxikon; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Research grant / Funding (institution): Taiho Pharmaceuticals; Research grant / Funding (institution): Toray Industries; Research grant / Funding (institution): Transgene; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Innate Pharma; Research grant / Funding (institution): Janssen. D. Loirat: Advisory / Consultancy: Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD. A. Tavernaro: Full / Part-time employment: Transgene SA. B. Bastien: Full / Part-time employment, Employed by sponsor of the study: Transgene SA. K. Bendjama: Shareholder / Stockholder / Stock options, Full / Part-time employment: Transgene.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract